Stress & Anxiety Dampening Effects of a Probiotic Supplement Compared to Placebo in Healthy Subjects

Daacro

Status

Completed

Conditions

Healthy

Stress, Psychological

Treatments

Dietary Supplement: Placebo

Dietary Supplement: Lpc-37

Study type

Interventional

Funder types

NETWORK

Industry

Identifiers

NCT03494725

DU01-2017

Details and patient eligibility

About

The aim of this study is to assess whether a 5 week intake of a probiotic (Lpc-37) can modulate stress and anxiety experienced by healthy subjects during and after an acute stressor compared to placebo. To measure stress and anxiety, markers of the hypothalamic-pituitary-adrenal (HPA) axis activity and questionnaires will be assessed before, during and after the Trier Social Stress Test (TSST). The results of this study indicate if the chosen study design is suitable to discover stress-related effects of probiotics.

Full description

The total mass of microorganisms residing within the human intestine is approximately the same as that of the human brain. Of late, these >1000 species and >7000 strains have been described as the "brain in our belly" because of the essential role they play in physiological and psychological health and disease. The gut-brain axis describes the bidirectional communication that exists between the brain and the gut and the microbiota-gut-brain axis supports the role of the gut microbiome in this communication system. Emotional and routine daily life stress can disrupt digestive function, but increasing evidence indicates that the gut microbiota exert a profound influence on brain physiology, psychological responses and ultimately behavior.

A plethora of literature to date, albeit predominantly preclinical, have demonstrated evidence to support the role of the gut microbiome in regulating stress-related changes in physiology, behavior and brain function.

Stress is an individual process to deal with external and internal challenges that ranges from behavioral to molecular adaptations. The HPA axis and its release of stress hormones plays a major role in stress adaptation.

The purpose of this clinical trial is to determine whether a single strain of bacteria derived from the species Lacticaseibacillus paracasei Lpc-37 (Lpc-37), formerly Lactobacillus paracasei Lpc-37, can modulate stress experienced by healthy subjects exposed to the TSST measured by HPA axis activation markers and self-report questionnaires.

Enrollment

120 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Voluntary, written, informed consent to participate in the study
Male or female aged between 18-45 years (inclusive)
Body mass index (BMI) between 18.5 - 29.9 kg/m2
Medical examination at baseline indicates they are healthy in the opinion of the investigator
Ability of the participant (in the Principal Investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects
Agreement to comply with the protocol and study restrictions
Available for all study visits
Females of child-bearing potential required to provide a negative urine pregnancy test and to use contraceptives
Easy access to internet

Exclusion criteria

Self-reported diagnosis of one or more Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV axis 1 disorder(s), including but not limited to current major depression, anxiety disorder, bipolar spectrum disorder or schizophrenia
Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD)), immunological, metabolic, neurodevelopmental or any condition which contraindicates, in the Investigator's judgement, entry to the study
Currently taking (from day of screening onwards) or have previously taken (last 4 weeks prior to screening) psychoactive medication (anxiolytics, sedatives, hypnotics, anti-psychotics, anti-depressants, anti-convulsants, centrally acting corticosteroids, opioid pain relievers)
Currently taking (from day of screening onwards) medication or dietary supplements that the Investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results (e.g. melatonin, omega-3 dietary supplements, non-steroidal anti-inflammatory drugs (NSAIDS), over-the-counter (OTC) sleep medication (not categorized as sedatives, hypnotics or anti-depressants), anti-coagulants, proton pump inhibitors, anti-histamines, pseudoephedrine, cortisone, beta-blockers)
Recent (within last 4 weeks prior to screening) or ongoing antibiotic therapy during the intervention period
Daily consumption of concentrated sources of probiotics and/or prebiotics within 2 weeks of screening and throughout the intervention period other than the provided study products (e.g., probiotic/prebiotic tablets, capsules, drops or powders)
Pregnant or lactating female, or pregnancy planned during intervention period
Not fluent in German
Have self-reported dyslexia
History of alcohol, drug, or medication abuse
Self-declared illicit drug users (including cannabis and cocaine) for 3 weeks prior to screening and during the intervention period
Contraindication to any substance in the investigational product
Hypertension (systolic ≥ 140 mmHg, diastolic ≥ 90 mmHg)
Known hyper- or hypothyroidism unless treated and under control (stable for more than 3 months)
Subjects having previously participated in the TSST
Smoking > 5 cigarettes/day
Employee of the sponsor or contract research organization (CRO)
Participation in another study with any investigational product within 60 days of screening and during the intervention period
Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study
Participant under administrative or legal supervision